BIO KEY INTERNATIONAL INC (BKYI): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:30 ET
- Event date
- 2026-11-13
- Accession no.
- 0001437749-26-036667
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
BIO-key reports Q3’26 results, with license fees up 39% and lower total revenue
BIO-key reported Q3’26 revenue of $1,482,781, down from $1,549,706, while license fee revenues rose 39%. Net loss narrowed to $(886,083) from $(964,849), but a non-cash deemed dividend related to the August warrant inducement increased net loss available to common stockholders to $(5,388,087).
- Q3’26 total revenues were $1,482,781 compared to $1,549,706 in Q3’25.
- Q3’26 license fee revenues increased 39% to $1,275,249; gross margin improved to 90% from 77%.
- Q3’26 net loss was $(886,083); a $4,502,004 deemed dividend brought loss available to common stockholders to $(5,388,087).
- BIO-key retired its remaining note payable through common stock exchanges, leaving a $12k bank obligation in Europe.
earningsdebt
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | bkyi20261112_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | ex_1044771.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.